Community/Retail

The American Society of Health-Systems Pharmacists 2018 Midyear Clinical Meeting is right around the corner, and Pharmacy Times will be on site in Anaheim, CA to cover the conference.

Immunotherapy was first linked to cancer treatment in the late 19th century when surgeon William Coley discovered that the injection of bacteria into sarcoma sites led to tumor shrinkage.

Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.

Your residency cover letter might be the most challenging part of the whole application process.

The drug’s application was designated for fast track and priority review, as well as orphan product status.

Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018, thus far.

CVS Health announced that it has closed its acquisition of Aetna with the promise to transform the consumer health experience.

Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine/Valsartan combination tablets and Amlodipine Valsartan/Hydrochlorothiazide combination tablets, due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India.

The Task Force notes in the draft recommendations that clinicians should screen everyone between the ages 15 to 65 years and all pregnant women for HIV.

The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have an NTRKgene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

FDA officials cited the possibility of a cardiovascular (CV) safety risk based on Zafgen's prior compound and outlined potential paths for moving forward.

More than 160 patients have thus far been treated with investigational therapeutics under an ethical framework developed by WHO.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Opioid use in the United States has exploded in recent years, from about 100 million prescriptions filled in 1992 to nearly 250 million in 2015.

In this series, Jill Drury, PharmD, a clinical pharmacy specialist, provides patients with "Brown Bag" consultations. Patients bring to the pharmacy their current medications and over-the-counter products, giving the pharmacist an additional resource for pharmaceutical counsel. In this video, a patient with Parkinson's disease is experiencing depression. He is a military veteran who is unsure of the medical instructions given by the VA.

Our editors want to know all about pharmacists' compensation and how happy they are with their jobs.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.

Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

The FDA today posted warning letters issued to 2 companies for the illegal marketing of products labeled as dietary supplements that contain tianeptine, a chemical compound that companies are illegally claiming treats opioid use disorder (OUD), pain and anxiety, and other unlawful and unproven claims.

The change aims to reinforce joint product development targets, accelerate the CGM products developer's efforts in type 2 diabetes, and improve its long-term profitability

Officials with the FDA have approved emapalumab (Gamifant) for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH), making it the first FDA-approved drug specifically indicated for this disease.

Although pharmacy schools are known for their advancements in pharmacy education, scientific discovery, and patient care, they still face an unspoken and universal truth shared among institutions of higher learning: students sometimes feel lost and unsure of themselves, and as if they have no one to whom they can turn.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

The FDA has approved lamivudine and tenofovir disoproxil fumarate (Temixys, Celltrion) tablets, 300 mg/300 mg in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.